Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Patrick Schöffski, Sant P. Chawla, Robert G. Maki, et al.
The Lancet (2016) Vol. 387, Iss. 10028, pp. 1629-1637
Open Access | Times Cited: 705

Showing 1-25 of 705 citing articles:

Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Paolo G. Casali, N. Abecassis, Sebastian Bauer, et al.
Annals of Oncology (2018) Vol. 29, pp. iv51-iv67
Open Access | Times Cited: 1504
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Hussein A. Tawbi, Melissa Burgess, Vanessa Bolejack, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 11, pp. 1493-1501
Open Access | Times Cited: 1160
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Margaret von Mehren, John M. Kane, Mark Agulnik, et al.
Journal of the National Comprehensive Cancer Network (2022) Vol. 20, Iss. 7, pp. 815-833
Open Access | Times Cited: 974
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
Alessandro Gronchi, Aisha Miah, Angelo Paolo Dei Tos, et al.
Annals of Oncology (2021) Vol. 32, Iss. 11, pp. 1348-1365
Open Access | Times Cited: 664
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
Sandra P. D’Angelo, Michelle R. Mahoney, Brian Andrew Van Tine, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 3, pp. 416-426
Open Access | Times Cited: 631
Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine
Adriana C. Gamboa, Alessandro Gronchi, Kenneth Cardona
CA A Cancer Journal for Clinicians (2020) Vol. 70, Iss. 3, pp. 200-229
Open Access | Times Cited: 419
UK guidelines for the management of soft tissue sarcomas
Adam Dangoor, Beatrice Seddon, Craig Gerrand, et al.
Clinical Sarcoma Research (2016) Vol. 6, Iss. 1
Open Access | Times Cited: 409
Clinical and Molecular Spectrum of Liposarcoma
Alex Thomas John Lee, Khin Thway, Paul H. Huang, et al.
Journal of Clinical Oncology (2017) Vol. 36, Iss. 2, pp. 151-159
Open Access | Times Cited: 284
Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma
Rolf D. Issels, Lars H. Lindner, Jaap Verweij, et al.
JAMA Oncology (2018) Vol. 4, Iss. 4, pp. 483-483
Open Access | Times Cited: 272
Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma
Yihebali Chi, Zhiwei Fang, Xiaonan Hong, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 21, pp. 5233-5238
Open Access | Times Cited: 270
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
William D. Tap, Zsuzsanna Pápai, Brian A. Van Tine, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 8, pp. 1089-1103
Open Access | Times Cited: 257
Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial
Olivier Mir, Thomas Brodowicz, Antoîne Italiano, et al.
The Lancet Oncology (2016) Vol. 17, Iss. 12, pp. 1732-1742
Closed Access | Times Cited: 235
Soft Tissue and Uterine Leiomyosarcoma
Suzanne George, César Serrano, Martee L. Hensley, et al.
Journal of Clinical Oncology (2017) Vol. 36, Iss. 2, pp. 144-150
Open Access | Times Cited: 197
Microtubule-targeting agents and their impact on cancer treatment
Vladimı́r Čermák, Vojtěch Dostál, Michael Jelínek, et al.
European Journal of Cell Biology (2020) Vol. 99, Iss. 4, pp. 151075-151075
Closed Access | Times Cited: 189
Chemotherapy for soft tissue sarcoma
Ravin Ratan, Shreyaskumar Patel
Cancer (2016) Vol. 122, Iss. 19, pp. 2952-2960
Open Access | Times Cited: 174
Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells
Naotaka Hayasaka, Kohichi Takada, Hajime Nakamura, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 156
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab
Ciara M. Kelly, Cristina R. Antonescu, Timothy G. Bowler, et al.
JAMA Oncology (2020) Vol. 6, Iss. 3, pp. 402-402
Open Access | Times Cited: 156
A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons
Javier Martín‐Broto, José L. Mondaza-Hernández, David S. Moura, et al.
Cancers (2021) Vol. 13, Iss. 12, pp. 2913-2913
Open Access | Times Cited: 105
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
Patricia Pautier, Antoîne Italiano, Sophie Piperno‐Neumann, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 8, pp. 1044-1054
Closed Access | Times Cited: 80
UK guidelines for the management of soft tissue sarcomas
Andrew Hayes, Ioanna Nixon, D. Strauß, et al.
British Journal of Cancer (2024)
Open Access | Times Cited: 18
Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study
M. Savina, Axel Le Cesne, Jean‐Yves Blay, et al.
BMC Medicine (2017) Vol. 15, Iss. 1
Open Access | Times Cited: 169
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma
Mrinal M. Gounder, Alona Zer, William D. Tap, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 26, pp. 3166-3174
Open Access | Times Cited: 151
Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine
George D. Demetri, Patrick Schöffski, Giovanni Grignani, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 30, pp. 3433-3439
Closed Access | Times Cited: 150
Marine Sponge Natural Products with Anticancer Potential: An Updated Review
Cinzia Calcabrini, Elena Catanzaro, Anupam Bishayee, et al.
Marine Drugs (2017) Vol. 15, Iss. 10, pp. 310-310
Open Access | Times Cited: 134
Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial
Javier Martín‐Broto, Nadia Hindi, Giovanni Grignani, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e001561-e001561
Open Access | Times Cited: 126
Page 1 - Next Page

Scroll to top